GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Captor Therapeutics SA (WAR:CTX) » Definitions » Gross-Profit-to-Asset %

Captor Therapeutics (WAR:CTX) Gross-Profit-to-Asset % : 10.44% (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Captor Therapeutics Gross-Profit-to-Asset %?

Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. Captor Therapeutics's annualized Gross Profit for the quarter that ended in Dec. 2023 was zł8.86 Mil. Captor Therapeutics's average Total Assets over the quarter that ended in Dec. 2023 was zł84.92 Mil. Therefore, Captor Therapeutics's annualized Gross-Profit-to-Asset % for the quarter that ended in Dec. 2023 was 10.44%.


Captor Therapeutics Gross-Profit-to-Asset % Historical Data

The historical data trend for Captor Therapeutics's Gross-Profit-to-Asset % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Captor Therapeutics Gross-Profit-to-Asset % Chart

Captor Therapeutics Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Gross-Profit-to-Asset %
Get a 7-Day Free Trial - - 3.83 5.51 6.56

Captor Therapeutics Quarterly Data
Dec17 Dec18 Jun19 Dec19 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Gross-Profit-to-Asset % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 16.87 4.13 11.17 5.59 10.44

Competitive Comparison of Captor Therapeutics's Gross-Profit-to-Asset %

For the Biotechnology subindustry, Captor Therapeutics's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Captor Therapeutics's Gross-Profit-to-Asset % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Captor Therapeutics's Gross-Profit-to-Asset % distribution charts can be found below:

* The bar in red indicates where Captor Therapeutics's Gross-Profit-to-Asset % falls into.



Captor Therapeutics Gross-Profit-to-Asset % Calculation

Captor Therapeutics's annualized Gross-Profit-to-Asset % for the fiscal year that ended in Dec. 2023 is calculated as:

Gross-Profit-to-Asset %=Gross Profit (A: Dec. 2023 )/( (Total Assets (A: Dec. 2022 )+Total Assets (A: Dec. 2023 ))/ count )
=6.901/( (113+97.294)/ 2 )
=6.901/105.147
=6.56 %

Captor Therapeutics's annualized Gross-Profit-to-Asset % for the quarter that ended in Dec. 2023 is calculated as:

Gross-Profit-to-Asset %=Gross Profit (Q: Dec. 2023 )/( (Total Assets (Q: Sep. 2023 )+Total Assets (Q: Dec. 2023 ))/ count )
=8.864/( (72.543+97.294)/ 2 )
=8.864/84.9185
=10.44 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Gross Profit data used here is four times the quarterly (Dec. 2023) data. Gross-Profit-to-Asset % is displayed in the 30-year financial page.


Captor Therapeutics Gross-Profit-to-Asset % Related Terms

Thank you for viewing the detailed overview of Captor Therapeutics's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.


Captor Therapeutics (WAR:CTX) Business Description

Traded in Other Exchanges
Address
ul. Dunska 11, Wroclaw, POL, 54-427
Captor Therapeutics SA is a biopharmaceutical company. It is focused on development of protein degradation drugs for cancer and autoimmune diseases, which have limited or no known treatment options.

Captor Therapeutics (WAR:CTX) Headlines

No Headlines